Instructions for trametinib combined with dabrafenib in the treatment of BRAF V600 mutated cancer and price analysis of each version

1. Dual-target mechanism: blocking tumor growth from upstream and downstream"Signal chain"

BRAF V600 mutation is a driver gene for various cancers such as melanoma and non-small cell lung cancer (NSCLC). The MAPK signaling pathway activated by it is like an out-of-control "signal chain" that continues to drive tumor cell proliferation. Trametinib/Mekinist, as a MEK1/2 inhibitor, cuts off signaling by blocking the MEK protein downstream of BRAF; Dabrafenib/TAFINLAR, as a BRAF V600 mutation-specific inhibitor, directly inhibits mutant BRAF kinase activity. The combined use of the two forms "upstream and downstream double blocking", which can effectively overcome single drug resistance and significantly improve the efficacy.

xa0

2. Expansion of indications: from melanoma to childhood tumors“Full cycle coverage”

In 2025, the indications of the dual-target program will cover the five major cancer types: melanoma, non-small cell lung cancer, thyroid cancer, low-grade glioma (LGG) and solid tumors, forming a "full-cycle, cross-cancer type" treatment pattern. Core indications include the following:

1) Melanoma: postoperative adjuvant treatment for unresectable or metastatic melanoma (combination/single drug) and stage III melanoma.

2) Non-small cell lung cancer (NSCLC): BRAF V600E mutation metastatic NSCLC (becoming the first approved lung cancer targeted program in 2023).

3) Thyroid cancer: locally advanced or metastatic anaplastic thyroid cancer (ATC).

4) Children’s tumors:

BRAF V600E mutated solid tumors (such as Langerhans cell histiocytosis) aged 6 years and older.

For low-grade glioma (LGG) aged 1 year and above, it can significantly improve the quality of life of children.

xa0

3. Usage and dosage: precise dose adjustment and management of special groups

1. Standard dose for adults:

1) Trametinib:2 mg/day, orally, combined with dabrafenib 150 mg.

2) Dabrafenib:150 mg orally twice a day, combined with 2 mg of trametinib.

2. Children’s dosage: Adjusted based on body weight and needs to be confirmed by genetic testingBRAF V600 mutation.

3. Dosage time: 1 hour before meals or 2 hours after meals. Avoid combination with strong inhibitors/inducers of CYP3A4/CYP2C8.

4. Management of special groups:

Liver function impairment: No dose adjustment is required for mild to moderate impairment, use with caution for moderate to severe impairment.

Renal function impairment: Mild to moderate, no adjustment is required, severe, toxicity needs to be monitored.

Elderly patients (≥65 years old): No initial dose adjustment is required, but adverse reactions need to be closely monitored.

Pediatric patients:Children with LGG under 6 years old need to calculate the dose based on body weight, and patients with glioma under 1 year old need individualized evaluation.

xa0

4.Clinical data support:

In BRAF V600E mutant melanoma, the objective response rate (ORR) of combination therapy reached 63.2%-76%, and the median progression-free survival (PFS) was 9.7-10.5 months.

InBRAF V600E mutated NSCLC, the ORR was 63.9%, the median PFS was 14.6 months, and the median overall survival (OS) was 24.6 months. China's real-world research shows that the median PFS of combination therapy in the first-line treatment of NSCLC is as long as 25 months, the 12-month PFS rate is 67%, and the 24-month PFS rate is 52%. More than half of the patients still benefit from taking the medicine for more than 2 years.

xa0

5. Price guide: The “cost-effectiveness battle” between original drugs and generic drugs

1.China Price (2025):

Trametinib (2mg×30 tablets): Ten thousand yuan/box;

Dabrafenib (75mg × 120 tablets): 10,000 yuan/box, the out-of-pocket cost is equivalent to that of trametinib.

The monthly cost of combined treatment is about more than 20,000 yuan.

2.Overseas price comparison:

Türkiye: The price of trametinib and dabrafenib is about 7,000 yuan per box, which is 30% lower than in China.

Generic drugs:

Lao Lucius version: Trametinib1 200 yuan per box, dabrafenib 2,100 yuan per box, the monthly cost is about more than 3,000 yuan, and the drug ingredients and safety of the generic drugs are basically the same as those of the original drugs.

xa0

6. Adverse reaction management: fever and skin toxicity"Reversibility Challenge"

1. Common adverse reactions (≥20%):

Fever (58%), rash (45%), fatigue (39%), diarrhea (32%), nausea (28%).

Severe adverse reactions (≥Grade 3): fever (5%), hypertension (4%), anemia (3%).

2. Management strategy:

Fever: When the body temperature is ≥38.5°C, medication is suspended and antipyretic and analgesic drugs (such as acetaminophen) are used. Medication is resumed after symptoms are relieved.

Skin toxicity: Apply topical hormone ointment (such as hydrocortisone). In severe cases, the dose needs to be reduced or discontinued.

Long-term monitoring: Eye examinations (to prevent uveitis) and liver function tests should be performed every every 3 months (drug discontinuation is required if ALT/AST increases >3 times).

xa0

7. Storage form of Qumedara

1. How to store Mekinist

Temperature requirements: Original drug instructions (FDA, EMA) recommend storage at 2°C–8°C (refrigerated conditions).

Do not freeze, avoid exposure to high temperatures or direct sunlight.

Shelf life after opening: Tablets should be stored in the original bottle, kept dry and protected from moisture.

Tighten the cap of the bottle immediately after each dose.

Special reminder: If you need to go out for a short period of time (≤30 days), some instructions allow storage at room temperature (not exceeding 30°C). It must be discarded after the expiration date.

xa0

2. Storage method of Dafinlar

Temperature Requirements: Should be stored at 20°C–25°C (room temperature), brief storage allowed within the range of 15°C–30°C.

Avoid placing it in humid or high-temperature areas such as bathrooms and kitchen stoves.

Moisture protection: Medication bottles often contain a desiccant, which must be retained in the bottle and not discarded or consumed.

The lid should be closed tightly every time after opening to reduce the entry of moisture.

Transportation Note: No refrigeration is required, but long-term exposure to the sun or high temperature in the car should be avoided.

xa0

3. Storage recommendations for combined use

Since the storage temperatures of the two drugs are different, do not mix them in the same container.

Trametinib needs to be refrigerated, while dabrafenib is stored at room temperature. It is recommended to store it separately in the medicine cabinet and label it to prevent misuse or misplacement.

If the patient travels or goes out, he/she needs to prepare a thermal bag (trametinib) and a dry sealed box (dabrafenib) and carry them with him. Do not check them in for prolonged exposure.

Trametinib and dabrafenib are effective drugs for the treatment of BRAF mutation-related tumors and have demonstrated good efficacy and safety in clinical practice. Although the current treatment costs are high, with the improvement of medical insurance policies and the popularity of generic drugs, more and more patients have the opportunity to obtain these innovative treatments. In the future, we hope that technological advancement will bring more choices and possibilities for tumor treatment.

References:

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-dabrafenib-trametinib-pediatric-patients-low-grade-glioma-braf-v600e-mutation?utm_source=chatgpt.com

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid?utm_source=chatgpt.com

https://www.nature.com/articles/s41598-025-07467-8?utm_source=chatgpt.com